Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies
Ji S, Liu H, Pachella L, Stephenson R, Groisberg R, Weiss S. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies. Frontiers In Transplantation 2023, 2: 1284740. PMID: 38993910, PMCID: PMC11235332, DOI: 10.3389/frtra.2023.1284740.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCutaneous squamous cell carcinomaObjective response rateMerkel cell carcinomaSolid organ transplant recipientsOrgan transplant recipientsSOT recipientsGraft rejectionCutaneous malignanciesCheckpoint inhibitorsTransplant recipientsCell carcinomaRetrospective analysisFirst-line immune checkpoint inhibitorsPrior systemic therapyAdvanced skin cancerSquamous cell carcinomaAdvanced cutaneous malignanciesImmunosuppressive therapyAllograft rejectionGraft failureSystemic therapyAdvanced melanomaCare therapyImmunosuppressive agentsA phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Davar D, Ikeguchi A, Buchbinder E, Shoushtari A, Seedor R, Bernicker E, Weiss S, Daniels G, Panella T, Ryan H, Goodall H, Sullivan R. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). Journal Of Clinical Oncology 2023, 41: tps9594-tps9594. DOI: 10.1200/jco.2023.41.16_suppl.tps9594.Peer-Reviewed Original ResearchMetastatic cutaneous melanomaMetastatic uveal melanomaAdvanced melanomaInvestigator's choicePrimary endpointDual primary endpointsOverall survival benefitPhase 3 trialSimilar patient populationsPhase 2/3 trialIC armOS benefitPrior ipilimumabRECIST responseInhibitor regimenSupportive careSurvival benefitCare therapyAnti-CTLA4CtDNA levelsTumor burdenInvestigational agentsPatient populationCutaneous melanomaClinical trials